Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by GameChangerBeton Jun 07, 2021 2:09pm
123 Views
Post# 33341359

RE:RE:RE:RE:RE:Hoping they provide an update soon

RE:RE:RE:RE:RE:Hoping they provide an update soonWait until the end of Phase III and FDA approval and commercial status. If you're not willing to wait for that event, perhaps consider selling your position and moving on with the option of revisiting.
You're relying on posts on stockhouse to guide your investments or your conviction in them?
Make a decision.
Stop with the daily nonsensical rhetoric.


StockingUp21 wrote:

seems more every day like a a scam here. You people say wait until next month every month. Only goes down and now is summer vacation?  


 

Actuarial wrote: You can choose to wait, or, you can sell your shares and walk away. Investing into a development stage bio / pharm company, ups and downs are the norm. Is it a surprise to you?

 

Layth1990 wrote: Summer vacation ? We already have been on a vacation since Q4 2021 as they postponed ph3 . If this is true then we will hit 3$ and will keep on bleeding.

 




<< Previous
Bullboard Posts
Next >>